TAG:
genetic tests
June 5, 2017 Intelligence: Late Breaking Lab News
By R. Lewis Dark | From the Volume XXIV No. 8 – June 5, 2017 Issue
Have you ever wondered how many consumers have ordered genetic tests from 23andMe? According to the MIT Technology Review, more than 2 million consumers have ordered genetic tests from the Silicon Valley company. Moreover, 85% of these consumers have consented to have their data use…
Lab’s Low Gene Test Price Gets Insurers’ Attention
By Joseph Burns | From the Volume XXIV No. 8 – June 5, 2017 Issue
CEO SUMMARY: At a time when most molecular and genetic testing companies are struggling to gain coverage for their tests, this Silicon Valley-based lab company has become an in-network lab provider for a number of health insurers—including three of the nation’s largest payers. It did …
Why It Matters That Your Lab Has Low Test Prices
By R. Lewis Dark | From the Volume XXIV No. 8 – June 5, 2017 Issue
TODAY, THE LAB INDUSTRY FACES A CONTRADICTION when setting prices for individual lab tests. At one extreme, a certain sector of labs seeking to win exclusive managed care contracts sets high-volume routine test prices at or below the fully-loaded cost to perform those tests. At another extreme, labor…
May 15, 2017 Intelligence: Late Breaking Lab News
By Robert Michel | From the Volume XXIV No. 7 – May 15, 2017 Issue
There is a new development in one of the whistleblower lawsuits filed against several lab companies that offered specialty cardiology tests. Earlier this month, the Department of Justice announced a settlement with Quest Diagnostics involving its acquisition of …
CEO Describes Characteristics Of the Clinical Lab 2.0 Model
By Joseph Burns | From the Volume XXIV No. 7 – May 15, 2017 Issue
CEO SUMMARY: Moving away from volume-based care will not be easy for clinical labs. After all, high volume sustains labs. But labs seeking to transition away from fee-for-service to value-based care must have a seat at the table where decisions are made, said a lab CEO who is part of Proj…
Congress Seems Ready to Tackle LDT Regulation
By R. Lewis Dark | From the Volume XXIV No. 6 – April 24, 2017 Issue
RECENT DEVELOPMENTS SIGNAL THAT THE FIGHT over FDA regulation of laboratory-developed tests (LDTs) is about to intensify. Last month, two Congressional representatives announced a new bill about LDTs that they said was a “discussion draft.” The bill is titled the “Diagnostic Accuracy and Innova…
Health Insurers Want More Data On Clinical Utility of Molecular, Genetic Tests
By Joseph Burns | From the Volume XXIV No. 4 – March 13, 2017 Issue
CEO SUMMARY: Genetic tests that lack two essentials are troublesome for the nation’s health insurers. Those essentials are clinical validity and clinical utility. During a recent webinar, two executives from major health insurers stressed the need for genetic testing labs to provide acc…
Health System Lab Is Genotyping To Identify Best Drugs for Patients
By Joseph Burns | From the Volume XXIV No. 2 – January 30, 2017 Issue
CEO SUMMARY: One essential element of precision medicine will be the regular use of pharmacogenomic testing to provide additional guidance to physicians when selecting the most appropriate therapeutics and optimal dose for each individual patient. Despite the reluctance of private payers …
PAMA Economics Drives Merger Of Two Seattle-Area Pathology Groups
By Joseph Burns | From the Volume XXIV No. 1 – January 9, 2017 Issue
CEO SUMMARY: Among the three chief reasons for the merger of CellNetix and Puget Sound Institute of Pathology, the most compelling was the need to address the challenges in the current reimbursement environment and to prepare for reductions in payment to pathologists expected in the comin…
Much Disruption for Labs In 2016’s Top 10 Stories
By Robert Michel | From the Volume XXIII, No. 17 – December 19, 2016 Issue
CEO SUMMARY: Within THE DARK REPORT’S list of the Top 10 Lab Industry Stories for 2016 is one story of disruption that might have been one story of disruption about to happen. The disintegration of Theranos during 2016 is the big story about a self-proclaimed disruptor of the lab indust…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized